Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does molecular monitoring matter in early-stage breast cancer?

Science translational medicine - 26 Aug 2015

Sundaresan Tilak K, Haber Daniel A

Abstract excerpt

Serial monitoring of circulating tumor DNA predicts recurrence after treatment for localized breast cancer (Garcia-Murillas et al., this issue).

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to DNA, Neoplasm
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26311727
DOI: 10.1126/scitranslmed.aac9445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does molecular monitoring matter in early-stage breast cancer?PMID 26311727Read ↗

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Circulating Tumor DNA in Breast Cancer: Current and Future Applications.Semantic proximity Read ↗

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Semantic proximity Read ↗

Circulating Tumor DNA to Monitor Metastatic Breast CancerSemantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance.Semantic proximity Read ↗

Circulating DNA as biomarker in breast cancer.Semantic proximity Read ↗

Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancerSemantic proximity Read ↗

Circulating Tumor DNA in Early and Metastatic Breast Cance—Current Role and What Is Coming NextSemantic proximity Read ↗

Breast cancer: Tracking ctDNA to evaluate relapse risk.Semantic proximity Read ↗

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapySemantic proximity Read ↗

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.